Bland embolization in patients with unresectable hepatocellular carcinoma using precise, tightly size-calibrated, anti-inflammatory microparticles: First clinical experience and one-year follow-up

CardioVascular and Interventional Radiology

Volumn 33, Issue 3, 2010, Pages 552-559

  Bonomo, Guido ^a   Pedicini, Vittorio ^b   Monfardini, Lorenzo ^a   Della Vigna, Paolo ^a   Poretti, Dario ^b   Orgera, Gianluigi ^a   Orsi, Franco ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

Author keywords

Chemoembolization; Embolization; Hepatocellular carcinoma; Microparticles

Indexed keywords

ALPHA FETOPROTEIN; AMYLASE; DIURETIC AGENT; MICROSPHERE;

ABDOMINAL DISEASE; ACCURACY; ADULT; AGED; ARTICLE; ARTIFICIAL EMBOLISM; ASCITES; BLAND EMBOLIZATION; CALIBRATION; CANCER CONTROL; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE CLASSIFICATION; FEASIBILITY STUDY; FEMALE; FOLLOW UP; HUMAN; LIVER CELL CARCINOMA; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MULTIDETECTOR COMPUTED TOMOGRAPHY; OVERALL SURVIVAL; PANCREATITIS; PRIORITY JOURNAL; RESPIRATORY FAILURE; SURVIVAL RATE; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR BIOPSY;

ACRYLIC RESINS; AGED; AGED, 80 AND OVER; BIOPSY; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; FEMALE; FOLLOW-UP STUDIES; GELATIN; HUMANS; LIVER NEOPLASMS; MALE; MICROSPHERES; MIDDLE AGED; POLYMERS; SURVIVAL RATE; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 77953138474     PISSN: 01741551     EISSN: 1432086X     Source Type: Journal    
DOI: 10.1007/s00270-009-9752-y     Document Type: Article

References (50)

1. Alba E, Valls C, Dominguez J et al (2008) Trancatheter arterial chemoembolization in patients with hepatocellular carcinoma on the waiting list for orthotopic liver transplantation. AJR 190(5):1341-1348
2. Parkin DM, Bray F, Ferlay J et al (2002) Global cancer statistics 2002. CA Cancer J Clin 55(2):74-108
3. El-Serag HB, Mason AC (1999) Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 340(10):745-750
4. El-Serag HB, Davial JA, Petersen NJ et al (2003) The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med 139(10):817-823
5. Llovet JM, Real MI, Montana X et al (2002) Arterial embolisation or chemoembolization versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359(9319):1734-1739
6. Schwartz M, Roayaie S, Konstadoulakis M (2007) Strategies for the management of hepatocellular carcinoma. Nat Clin Pract Oncol 4(7):424-432
7. Clark HP, Carson WF, Kavanagh PV et al (2005) Staging and current treatment of hepatocellular carcinoma. Radiographics 25 (Suppl 1): S3-S23
8. Llovet JM, Burroughs A, Bruix J (2003) Hepatocellular carcinoma. Lancet 362(9399):1907-1917 [review]
9. Lubienski A (2005) Hepatocellular carcinoma: interventional bridging to liver transplantation. Transplantation 80(Suppl 1):S113-S119
10. Bruix J, Sala M, Llovet JM (2004) Chemoembolization for hepatocellular carcinoma. Gastroenterology 127 (5 Suppl 1):179-188
11. Camma C, Schepis F, Orlando A et al (2002) Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled. Radiology 224(1):47-54
12. Llovet JM, Bruix J (2003) Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 37(2):429-442
13. Bruix J, Sherman M, Llovet JM et al (2001) Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL Conference, for the EASL Panel of Experts on HCC. J Hepatol 35(3):421-430
14. Arakawa A, Nishiharu T, Matsukawa T et al (1996) Detection of hepatocellular carcinoma by intraarterially enhanced ultrasonography with CO2 microbubbles. Comparison with DSA, dynamic CT, and Lipiodol CT. Acta Radiol 37 (3 Pt 1):250-254
15. Merlino R, Orsi F, Bezzi M et al (1994) Carbon dioxide as an intra-arterial contrast agent in echography: a technique for its preparation and the preliminary results in assessing hepatocarcinoma vascularisation. Radiol Med 88(3):259-265
16. Salem R, Thurston KG (2006) Radioembolization with 90yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 1: Technical and methodologic considerations. J Vasc Interv Radiol 17(8):1251-1278 (Pubitemid 44259009)
17. Chen JH, Chai JW, Huang CL et al (1999) Proximal arterioportal shunting associated with hepatocellular carcinoma: features revealed by dynamic helical CT. AJR 172(2):403-407
18. Hung JC, Redfern MG, Mahoney DW et al (2000) Evaluation of macroaggregated albumin particle sizes for use in pulmonary shunt patient studies. J Am Pharm Assoc 40(1):46-51
19. Brown DB, Cardella JF, Sacks D et al (2006) Quality improvement guidelines for transhepatic arterial chemoembolization, embolization and chemotherapeutic infusion for hepatic malignancy. J Vasc Interv Radiol 17:225-232
20. Llovet JM, Brù C, Bruix J (1999) Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 19(3):329-339
21. Lo CM, Ngan H, Tso WK et al (2002) Randomized controlled trial of trasarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35(5):1164-1171
22. Miraglia R, Pietrosi G, Maruzzelli L et al (2007) Efficacy of transcatheter embolization/chemoembolization (TAE/TACE) for the treatment of single hepatocellular carcinoma. World J Gastroenterol 13(21):2953-2955
23. Lin DY, Lee TY, Liaw YF et al (1988) Hepatic arterial embolization in patients with unresectable hepatocellular carcinoma: a randomized controlled trial. Gastroenterology 94(2):453-456
24. Pelletier G, Roche A, Ink O et al (1990) A randomized trial of hepatic arterial chemoembolization in patient with unresectable hepatocellular carcinoma. J Hepatol 11(2):181-184
25. Madden MV, Krige JE, Bailey S et al (1993) Randomised trial of targeted chemotherapy with lipiodol and 5-epidoxorubicin compared with symptomatic treatment for hepatoma. Gut 34(11):1598-1600
26. Bruix J, Llovet JM, Castells A et al (1998) Transarterial embolization versus symptomatic treatment in patients with advanced HCC: results of randomized controlled trial in a single institution. Hepatology 27(6):1578-1583
27. Pelletier G, Ducreux M, Gay F et al (1998) Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. J Hepatol 29(1):129-134
28. Grosso M, Vignali C, Quaretti P et al (2008) Transarterial chemoembolization for hepatocellular carcinoma with drugeluting microspheres: preliminary results from an Italian multicentre study. Cardiovasc Interv Radiol 31(6):1141-1149
29. Marelli L, Stigliano R, Triantos C et al (2007) Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Interv Radiol 30(1):6-25
30. Llovet JM, Real MI, Montana X et al (2002) Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359:1734-1739
31. Ramsey DE, Kernagis LY, Soulen MC et al (2002) Chemoembolization of hepatocellular carcinoma. J Vasc Interv Radiol 13 (9; Pt 2):211-221
32. Mathupala SP, Rempel A, Pedersen PL (2001) Glucose catabolism in cancer cells: identification and characterization of a marked activation response of the type II hexokinase gene to hypoxic conditions. J Biol Chem 276(46):43407-43412
33. Tajima T, Honda H, Taguchi K et al (2002) Sequential hemodynamic change in hepatocellular carcinoma and dysplastic nodules: CT angiography and pathologic correlation. AJR 178(4):885-897
34. Lee KH, Liapi E, Vossen JA et al (2008) Distribution of iron oxide-containing embosphere particles after transcatheter arterial embolization in an animal model of liver cancer: evaluation with MR imaging and implicationfor therapy. J Vasc Interv Radiol 19:1490-1496
35. Jones JA, Chang DT, Meyerson H et al (2007) Proteomic analysis and quantification of cytokines and chemokines from biomaterial surface-adherent macrophages and foreign body giant cells. J Biomed Mater Res A 83:585-596
36. Kobayashi N, Ishii M, Ueno Y et al (1999) Co-expression of Bel-2 protein and vascular endothelial growth factor in hepatocellular carcinomas treated by chemoembolization. Liver 19(1):25-31
37. Liou TC, Shih SC, Kao CR et al (1995) Pulmonary metastasis of hepatocellular carcinoma associated with transarterial chemoembolization. J Hepatol 23(5):563-568
38. Sergio A, Cristofori C, Cardin R et al (2008) Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness. Am J Gastroenterol 103(4):914-921
39. Mamori S, Asakura T, Ohkawa K et al (2007) Survivin expression in early hepatocellular carcinoma and post-treatment with anticancer drug under hypoxic culture condition. World J Gastroenterol 13(40):5306-5311
40. Laurent A, Wassef M, Chapot R et al (2004) Location of vessel occlusion of calibrated tris-acryl gelatin microspheres for tumor and arteriovenous malformation embolization. J Vasc Interv Radiol 15:491-496
41. Dion JE, Rankin RN, Vinuela F et al (1986) Dextran microsphere embolization: experimental and clinical experience with radiologic-pathologic correlation. Radiology 160:717-721
42. Pillaj KM, McKeever PE, Knutsen CA et al (1991) Microscopic analysis of arterial microsphere distribution in rabbit liver and hepatic VX2 tumor. Sel Cancer Ther 7(2):39-48
43. Yamamoto A, Imai S, Kobatake M et al (2006) Evaluation of trisacryl gelatine microsphere embolization with monochromatic X-rays: comparison with polyvinyl alcohol particles. J Vasc Interv Radiol 17:1797-1802
44. Lee KH, Liapi E, Vossen JA et al (2008) Distribution of iron oxide-containing Embosphere particles after transcatheter arterial embolization in an animal model of liver cancer: evaluation with MR Imaging and implication for therapy. J Vasc Interv Radiol 19(10):1490-1496
45. Amseur NB, Zajko AB, Carr BI (2008) Chemo-embolization for unresectable hepatocellular carcinoma with different sizes of embolization particles. Dig Dis Sci 53(5):1400-1404
46. Maluccio MA, Covey AM, Porat LB et al (2008) Transcatheter arterial embolization with only particles for the treatment of unresectable hepatocellular carcinoma. J Vasc Interv Radiol 19(6):862-869
47. Stampfl U, Stampfl S, Bellemann N et al (2009) Experimental liver embolization with four different spherical embolic materials: impact on inflammatory tissue and foreign body reaction. Cardiovasc Interv Radiol 32(2):303-312
48. Bilbao JI, de Martino A, de Luis E et al (2009) Biocompatibility, inflammatory response, and recannalization characteristics of nonradioactive resin microspheres: histological findings. Cardiovasc Interv Radiol 32(4):727-736
49. Brown KT (2004) Fatal pulmonary complications after arterial embolization with 40-120 μm tris-acryl gelatine microspheres. J Vasc Interv Radiol 15 (2; Pt 1):197-200
50. Noguera P J J, Martinez-Cuesta A, Sangro B et al (2008) Embolismo pulmonary fatal tras la embolizaciòn con microsferas de un hepatocarcinoma. Radiologia 50:248-250